Joint venture Klothonova has shown GMP-banked Klotho-producing cells remain viable and secrete therapeutic protein inside Cell-in-a-Box capsules.

The Los Angeles CAR-T company raised $125m at $11.00 per share, with J.P. Morgan sole book-runner and backing from Wellington and

NorthStrive Biosciences has signed a statement of work with Charles River Laboratories to characterise plasmid copy numbers in its EL-22 and EL-32 engineered

AAVantgarde Bio presented Phase 1/2 data showing visual function gains in Usher syndrome and strong preclinical support for its Stargardt programme at EURetina 2026.

Nasdaq-listed Cuprina is buying East Coast Podiatry and Orchard Clinic to integrate clinical delivery with its wound-care and collagen technologies.

ProKidney will share Phase 2 pooled data and preclinical mechanistic evidence for rilparencel at ASN Kidney Week in Denver, 21-25 October.

Psyence BioMed's Texas subsidiary has signed a binding term sheet granting exclusive US rights to PsyLabs' pharmaceutical-grade ibogaine, ahead of a planned development

A Spherix Global Insights survey shows physician confidence in autologous CAR-T fell sharply after trial pauses at Novartis and Bristol Myers Squibb.

A new US patent extends IP protection for DARE-HPV to at least 2039 as the Phase 2 trial progresses, backed by $12m in non

The cryopreservation system's Type II DMF lets cell therapy developers cross-reference regulatory documentation in IND and BLA submissions.

Ernexa Therapeutics has appointed oncology veteran Robert Spiegel to its board as it targets a Q4 2026 IND filing for its lead iMSC cell therapy.

New Category I CPT codes covering Inspire V's single-lead hypoglossal nerve stimulator are set to take effect on 1 January 2028.